PDL Biopharma (PDLI) 10-K2013 FY Annual report

Filed: 3 Mar 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: AAA, Abbot, academic, accomplish, accomplished, accrual, adjuvant, affiliated, atherectomy, attainment, Avinger, AXGN, beneficiary, blended, Boehringer, breakthrough, bring, canagliflozin, catheter, certainty, chlorambucil, chronic, CLL, complicate, complying, confirmed, contesting, dalbavancin, delay, Depo, Depomed, device, difficulty, discretion, domestic, DR, drawn, Durata, eleventh, EMA, entry, EU, evenly, expert, facsimile, Fargo, finite, frequency, Gazyva, German, Glumetza, goal, HCL, headquartered, healthcare, illiquidity, indefinitely, Ingelheim, innovate, inoperable, inspection, insufficient, investigational, Invokana, Janssen, Janumet, Japan, joined, Kadcyla, Korea, large, Laser, LENSAR, leverage, LG, licensor, lien, linker, lumivascular, lymphocytic, metformin, overallotment, Paradigm, Pharmaceutica, power, prepayment, proposed, quickly, RBC, recoverable, representation, resale, reset, restated, Royal, short, sitagliptin, Spine, stable, statute, strategic, stream, successfully, suffer, surgery, taxane, thirteenth, tranche, trastuzumab, twelfth, uncooperative, undiscounted, untreated, Valeant, vi, vii, waived, warranty, XR

Removed: agency, alleged, arisen, assert, basic, complaint, County, coupling, cytotoxic, declaring, discontinued, District, drop, efficiently, enforceable, exemption, experimental, fail, fighting, incur, internationally, Judicial, killing, launched, list, organized, paper, positive, potentially, prevail, receipt, redeemable, registration, reliance, reserve, response, seeking, shift, Singapore, sponsored, suggest, suit, thereunder, today, treasury, trial, tumor, unsecured, vigorously, Washoe

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PDLI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), John P. McLaughlin, Chief Executive Officer of PDL BioPharma, Inc. (the “Company”), and Peter S. Garcia, Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

(1) The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and

(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 3, 2014



	By:
		/s/ JOHN P. MCLAUGHLIN
		John P. McLaughlin
		President and Chief Executive Officer
		(Principal Executive Officer)


	By:
		/s/ PETER S. GARCIA
		Peter S. Garcia
		Vice President and Chief Financial Officer
		(Principal Financial Officer)

_________________________________________

(1)

This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of PDL BioPharma, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to PDL BioPharma, Inc. and will be retained by PDL BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.